175 related articles for article (PubMed ID: 27323954)
1. Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes.
Suzuki Y; Tomita A; Nakamura F; Iriyama C; Shirahata-Adachi M; Shimada K; Akashi A; Ishikawa Y; Kaneda N; Kiyoi H
Cancer Sci; 2016 Sep; 107(9):1329-37. PubMed ID: 27323954
[TBL] [Abstract][Full Text] [Related]
2. High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS).
Mohamedali AM; Gäken J; Ahmed M; Malik F; Smith AE; Best S; Mian S; Gaymes T; Ireland R; Kulasekararaj AG; Mufti GJ
Leukemia; 2015 Sep; 29(9):1928-38. PubMed ID: 25943179
[TBL] [Abstract][Full Text] [Related]
3. Using peripheral blood circulating DNAs to detect CpG global methylation status and genetic mutations in patients with myelodysplastic syndrome.
Iriyama C; Tomita A; Hoshino H; Adachi-Shirahata M; Furukawa-Hibi Y; Yamada K; Kiyoi H; Naoe T
Biochem Biophys Res Commun; 2012 Mar; 419(4):662-9. PubMed ID: 22382018
[TBL] [Abstract][Full Text] [Related]
4. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
[TBL] [Abstract][Full Text] [Related]
5. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.
Tamaki H; Ogawa H; Ohyashiki K; Ohyashiki JH; Iwama H; Inoue K; Soma T; Oka Y; Tatekawa T; Oji Y; Tsuboi A; Kim EH; Kawakami M; Fuchigami K; Tomonaga M; Toyama K; Aozasa K; Kishimoto T; Sugiyama H
Leukemia; 1999 Mar; 13(3):393-9. PubMed ID: 10086730
[TBL] [Abstract][Full Text] [Related]
6. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.
Cilloni D; Gottardi E; Messa F; Fava M; Scaravaglio P; Bertini M; Girotto M; Marinone C; Ferrero D; Gallamini A; Levis A; Saglio G;
J Clin Oncol; 2003 May; 21(10):1988-95. PubMed ID: 12743153
[TBL] [Abstract][Full Text] [Related]
7. Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes.
Aoki E; Uchida T; Ohashi H; Nagai H; Murase T; Ichikawa A; Yamao K; Hotta T; Kinoshita T; Saito H; Murate T
Leukemia; 2000 Apr; 14(4):586-93. PubMed ID: 10764143
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.
Duong VH; Padron E; Al Ali NH; Lancet JE; Hall J; Kwok B; Zhang L; Epling-Burnette PK; List AF; Komrokji RS
Ann Hematol; 2018 Feb; 97(2):247-254. PubMed ID: 29167940
[TBL] [Abstract][Full Text] [Related]
9. Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome.
Mohamedali AM; Alkhatabi H; Kulasekararaj A; Shinde S; Mian S; Malik F; Smith AE; Gäken J; Mufti GJ
Blood; 2013 Jul; 122(4):567-70. PubMed ID: 23760614
[TBL] [Abstract][Full Text] [Related]
10. Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes.
Yeh P; Dickinson M; Ftouni S; Hunter T; Sinha D; Wong SQ; Agarwal R; Vedururu R; Doig K; Fong CY; Blombery P; Westerman D; Dawson MA; Dawson SJ
Blood; 2017 Mar; 129(12):1685-1690. PubMed ID: 28126926
[TBL] [Abstract][Full Text] [Related]
11. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
12. Associations between the peripheral blood Wilms tumor gene 1 level and both bone marrow blast cells and the prognosis in patients with myelodysplastic syndrome.
Mashima K; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Fujiwara S; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Leuk Lymphoma; 2019 Mar; 60(3):703-710. PubMed ID: 30188227
[TBL] [Abstract][Full Text] [Related]
13. [Expression of WT1 and PRAME gene in bone marrow and peripheral blood samples of patients with myelodysplastic syndrome].
Lu D; Qin YZ; Li LD; Shi HX; Lai YY; Liu YR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):370-6. PubMed ID: 24763007
[TBL] [Abstract][Full Text] [Related]
14. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
[TBL] [Abstract][Full Text] [Related]
15. Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Chaudhary AK; Chaudhary S; Ghosh K; Shanmukaiah C; Nadkarni AH
Asian Pac J Cancer Prev; 2016; 17(3):1519-29. PubMed ID: 27039800
[TBL] [Abstract][Full Text] [Related]
16. Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes.
Christopeit M; Badbaran A; Alawi M; Zabelina T; Zeck G; Wolschke C; Ayuk F; Kröger N
Eur J Haematol; 2016 Sep; 97(3):288-96. PubMed ID: 26680262
[TBL] [Abstract][Full Text] [Related]
17. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA.
Jilani I; Estey E; Manshuri T; Caligiuri M; Keating M; Giles F; Thomas D; Kantarjian H; Albitar M
Leukemia; 2003 Jan; 17(1):114-9. PubMed ID: 12529667
[TBL] [Abstract][Full Text] [Related]
18. [Relationship between clinical features and somatic gene mutations in myelodysplastic syndrome].
Hirasawa N; Sakata-Yanagimoto M; Nannya Y; Hattori K; Suehara Y; Kato T; Yokoyama Y; Kurita N; Obara N; Ogawa S; Hasegawa Y; Chiba S
Rinsho Ketsueki; 2018; 59(1):80-83. PubMed ID: 29415943
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.
Ueda Y; Mizutani C; Nannya Y; Kurokawa M; Kobayashi S; Takeuchi J; Tamura H; Ogata K; Dan K; Shibayama H; Kanakura Y; Niimi K; Sasaki K; Watanabe M; Emi N; Teramura M; Motoji T; Kida M; Usuki K; Takada S; Sakura T; Ito Y; Ohyashiki K; Ogawa H; Suzuki T; Ozawa K; Imai K; Kasai M; Hata T; Miyazaki Y; Morita Y; Kanamaru A; Matsuda A; Tohyama K; Koga D; Tamaki H; Mitani K; Naoe T; Sugiyama H; Takaku F
Leuk Lymphoma; 2013 Jul; 54(7):1450-8. PubMed ID: 23110324
[TBL] [Abstract][Full Text] [Related]
20. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
